In This Section

Program

Please note that this symposium will take place as an in-person event in Montreal and will not live-stream content for virtual participation. The symposium content will be recorded and made available as an on-demand program after the symposium. Please visit the registration page for details.

CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Monday, June 10

Tuesday, June 11

Wednesday, June 12

Thursday, June 13

Monday, June 10

welcome and introductions
6-6:05 P.M.

  • Michael A. Erb, The Scripps Research Institute, La Jolla, California
  • Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts
  • E. Alejandro Sweet-Cordero, University of California, San Francisco, California
  • Kris C. Wood, Duke University School of Medicine, Durham, North Carolina

Opening Plenary
6-7 P.M.
CME-Eligible

  • Scientific Keynote
    Exploiting pathway activation as a new form of synthetic lethality
    William R. Sellers, Broad Institute and Dana-Farber Cancer Institute, Cambridge, Massachusetts 

OPENING RECEPTION
7-8:30 P.M.

Tuesday, June 11

CONTINENTAL BREAKFAST
7-8 A.M.

PLENARY SESSION 1: Chemical Biology Tools to Advance Synthetic Lethality
8-10 a.m.
CME-Eligible

Session Chair: Fleur M. Ferguson, UC San Diego, La Jolla, California

  • Overcoming the K-Ras inhibitor resistant cell state in PDAC with molecular glues
    Fleur M. Ferguson
  • Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase
    Matthew P. Patricelli, Vividion Therapeutics, San Diego, California
  • Redirecting FOXA1 pioneering function with covalent small molecules 
    Michael A. Erb, The Scripps Research Institute, La Jolla, California
  • KIF18A inhibition, via ATX020, leads to mitotic arrest and robust anti-tumor activity through a synthetic lethal interaction with chromosome instability* 
    Maureen Lynes, Accent Therapeutics, Lexington, Massachusetts
  • Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer* 
    Yonghao Yu, Columbia University Vagelos College of Physicians and Surgeons, New York, New York 

BREAK
10-10:30 A.M.

PLENARY SESSION 2: Mechanisms of Synthetic Lethality
10:30 A.M.-12:30 P.M.
CME-Eligible

Session Chair: Zuzana Tothova, Dana-Farber Cancer Institute, Boston, Massachusetts 

  • Therapeutic vulnerabilities of cohesin-mutant myeloid malignancies 
    Zuzana Tothova
  • Synthetic lethalities for SWI/SNF mutant cancers
    Charles W.M. Roberts, St. Jude Children’s Research Hospital, Memphis, Tennessee 
  • The long isoform  of RAP1GDS1 is a synthetic vulnerability in RAS-driven lung adenocarcinoma
    E. Alejandro Sweet-Cordero, University of California San Francisco, San Francisco, California 
  • Mechanisms of therapeutic vulnerability of mismatch repair defective cancers to RNA polymerase I inhibitors* 
    Marikki Laiho, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 
  • Computational discovery of paralog dependencies drives target identification in lung cancer* 
    Siobhan O’Brien, Fred Hutchinson Cancer Center, Seattle, Washington 

LUNCH (ON OWN)
12:30-2:30 P.M.

Plenary Session 3: Clinical Translation of DNA Damage Synthetic Lethality
2:30-4:30 P.M.
CME-Eligible

Session Chair: Michael A. White, Ideaya Biosciences, San Diego, California 

  • Exploiting tumor selective vulnerabilities with structure based drug design 
    Michael A. White
  • Single strand DNA GAP accumulation as a functional biomarker for DNA repair inhibitors
    Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, Massachusetts 
  • Targeting genome instability in cancer: Translating synthetic lethal biology into the clinic 
    Michael J. Zinda, Repare Therapeutics Inc., Cambridge, Massachusetts 
  • CX-5461 sensitizes DNA damage repair-proficient castrate-resistant prostate cancer to PARP inhibition* 
    Luc Furic, Peter MacCallum Cancer Centre, Melbourne, Australia 
  • DNA repair inhibition via targeting ATR activates cGAS/STING signaling, promotes anti-tumor immunity, and is a synthetic lethal strategy to augment immunotherapy response in preclinical models and clinical samples of small cell lung cancer* 
    Triparna Sen, Icahn School of Medicine at Mount Sinai, New York, New York 

Poster session A and reception
4:30-7 P.M.

Wednesday, June 12

CONTINENTAL BREAKFAST
7-8 A.M.

Plenary Session 4: Synthetic Lethality at Scale
8-10 A.M.
CME-Eligible

Session Chair: Francisca Vazquez, Broad Institute, Cambridge, Massachusetts 

  • Towards mapping the landscape of cancer vulnerabilities 
    Francisca Vazquez 
  • Mapping genetic dependencies and Interactions in childhood brain cancers
    Ron Firestein, Hudson Institute of Medical Research, Clayton, Australia 
  • Identifying novel therapeutic vulnerabilities in AML: From discovery to targeting
    Aniruddha Deshpande, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 
  • Delineating functional drivers of esophageal adenocarcinoma to identify synthetic lethal interactions* 
    Nicholas Clemons, Peter MacCallum Cancer Centre, Melbourne, Australia 
  • Targeting mechanisms of dosage compensation to selectively kill aneuploid cancer cells* 
    Hajime Okada, Tel Aviv University, Tel Aviv, Israel 

BREAK
10-10:30 A.M.


Plenary Session 5: New Concepts in Synthetic Lethality
10:30 A.m.-12:30 p.M.
CME-Eligible

Session Chair: Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts

  • Synthetic lethal vulnerabilities in pediatric cancer
    Kimberly Stegmaier
  • Identifying and targeting synthetic lethalities of aneuploid (cancer) cells
    Uri Ben-David, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  • Emerging synthetic vulnerabilities in oncogene-driven lung cancer
    Trever G. Bivona, University of California San Francisco, San Francisco, California 
  • Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal cancers* 
    Tim Arnoldus, Netherlands Cancer Institute, Amsterdam, Netherlands 
  • CDK12 loss promotes prostate cancer development while exposing vulnerabilities to paralog-based synthetic lethality* 
    Jean C. Tien, University of Michigan, Ann Arbor, Michigan 

LUNCH ON OWN
12:30-2:30 P.M.

Plenary Session 6: Synthetic Lethality of Residual Disease and Novel Drug Combinations
2:30-4:30 P.M.
CME-Eligible

Session Chair: Kris C. Wood, Duke University, Durham, North Carolina

  • Synthetic dependencies arising during tumor evolution 
    Kris C. Wood
  • Vulnerabilities of TP53-mutated AML and therapeutic implications
    Shruti Bhatt, National University of Singapore (NUS), Singapore 
  • Identification of metabolic adaptation mechanisms that confer resistance to glutathione depletion in Ewing sarcoma
    Poul H.B. Sorensen, British Columbia Cancer Research Institute and University of British Columbia, Vancouver, British Columbia, Canada 
  • Inhibiting eIF4E phosphorylation sensitizes triple-negative breast cancer to CDK4/6 inhibition* 
    Qiyun Deng, McGill University, Montreal, Quebec, Canada 
  • KAT6A/B and Menin-MLL complexes coordinately regulate estrogen receptor-driven gene expression programs in breast cancer* 
    Sarah Naomi Olsen, Dana-Farber Cancer Institute, Boston, Massachusetts 

Poster session b and reception
4:30-7 P.M.

Thursday, June 13

CONTINENTAL BREAKFAST
7-8 A.M.

Plenary Session 7: New Technologies to Discover Synthetic Lethality
8-10 A.M.
CME-Eligible

Session Chair: Francisco J. Sánchez Rivera, Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts

  • Functional studies of genetic variation using precision genome editing
    Francisco J. Sánchez Rivera
  • Environmental challenge rewires functional connections among human genes
    Luke A. Gilbert, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California 
  • Mechanisms of splicing dysregulation and dependency in cancer
    Kristen L. Karlin, Baylor College of Medicine, Houston Texas
  • Detecting pairwise and higher-order antagonistic epistatic effects among somatic cancer genotypes to discover synthetic lethality* 
    Jorge A. Alfaro-Murillo, Yale University, New Haven, Connecticut 
  • Combinatorial genetic screens to map synthetic lethal interactions and identify new cancer drug targets in KRAS mutant cancers* 
    Rand Arafeh, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 

BREAK
10-10:30 A.M.

Plenary Session 8: Translating the Next Synthetic Lethalities
10:30 A.m.-12:30 p.M.
CME-Eligible

Session Chair: Jolanta E. Grembecka, University of Michigan, Ann Arbor, Michigan 

  • Targeting epigenetic complexes in leukemia 
    Jolanta E. Grembecka
  • RNA-modifying enzyme inhibitors as synthetic lethal cancer therapeutics 
    Serena J. Silver, Accent Therapeutics, Lexington, Massachusetts 
  • Identifying and deconstructing chemical synthetic lethal interactions for the development of combinatorial therapies
    Karen M. Cichowski, Brigham and Women’s Hospital, Boston, Massachusetts
  • Discovery of selective BRM (SMARCA2) ATPase inhibitors for the treatment of BRG1(SMARCA4) mutant cancers* 
    Janice Y. Lee, Foghorn Therapeutics, Cambridge, Massachusetts 
  • Investigating vulnerabilities associated with chromosome arm aneuploidy in cancer* 
    Nadja Zhakula, Columbia University Vagelos College of Physicians and Surgeons, New York, New York 

CLOSING REMARKS
12:30 P.m.
CME-Eligible

  • Michael A. Erb, The Scripps Research Institute, La Jolla, California  
  • Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts 
  • E. Alejandro Sweet-Cordero, University of California, San Francisco, California 
  • Kris C. Wood, Duke University School of Medicine, Durham, North Carolina